BenevolentAI Investor Conference Presentation Deck

The Al value proposition for pharma R&D Direct R&D Cost Savings Discovery & Pre-Clinical "Faster and cost effective" INDUSTRY STANDARD $33m over 5.5 years AI-ENHANCED $15m over 3-3.5 years Based on industry benchmarks and internal programmes Reduce pre-clinical cost by >50% and time to market by 2-2.5 years Note Lab research and target identification costs and time not captured in industry data - likely to add significantly to the industry standard time and cost Notes and Sources: For illustrative purposes only; (1) Illustrative NPV for a theoretical $750m peak sales drug during initial 10Y on the market (assumes (i) peak sales reached 5 years post-launch, (ii) 90% gross margin, (iii) 20% S&M expenses, (iv) 20% tax, (v) a 10% discount rate) and (vi) excludes any terminal value). (2) Based on Paul et al Nat Rev Drug Discov 2010. (3) Based on Harrison, Nat Rev Drug Discov 2016. (4) Based on Biomedtracker/Pharmalntelligence 2021. (5) Based on Odyssey Due Diligence report. PoS from Phase I to Market "Get it right more often" Highest attrition is at Phase II (current 34% success rate) (2) ~50% Phase II/III trial failures due to lack of efficacy (3) # Phase I Candidates Required for 1 Approved Drug Increasing Probability of Success Illustrative NPV(¹) Clinical Development INDUSTRY STANDARD 12% 9 c$60m AI-ENHANCED (ILLUSTRATIVE) 24% c$200m Illustrative 25% POS improvement at each clinical stage (Phase I-III) Context • Phase II trials with pre-selection biomarkers already >50% more likely to succeed (4) Industry experts estimate that the use of Al can improve the PoS of each phase by up to 45% (5) Benevolent 6

View entire presentation